[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552147":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":28,"locations":38,"responsibleParty":55,"collaborators":57,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":23,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":32,"enrollmentInfo":72,"targetDuration":32,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":40,"whyStopped":32,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"DIVERSE Community Advisory Board (CAB)","Enrolled participants will complete:\n\n* Confidentiality agreement and demographic questionnaire\n* Online training and in-person or remote training with study team\n* Timely DIVERSE review of protocols\n* Audio recorded meeting (in-person, remote, or via phone call) with study team to present review findings\n* Semi-structured exit interview and\u002For focus group with study staff to provide feedback",[12],"Other: DIVERSE Review Process",{"label":14,"type":6,"description":15,"interventionNames":16},"DIVERSE Investigators","Enrolled investigator participants will complete:\n\n* Brief Feedback Survey\n* Request DIVERSE reviews and complete request form\n* Acceptability of Intervention Measure questionnaire\n* Semi-structured exit interview and\u002For focus group with study staff to provide feedback",[12],[18],{"type":6,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DIVERSE Review Process","A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.",[9,14],[23],"DIVERSE",[25],{"name":26,"affiliation":5,"role":27},"Andrew Hantel, MD","PRINCIPAL_INVESTIGATOR",[29,34],{"name":26,"role":30,"phone":31,"phoneExt":32,"email":33},"CONTACT","617-582-9394",null,"Andrew_Hantel@dfci.harvard.edu",{"name":35,"role":30,"phone":36,"phoneExt":32,"email":37},"Oldy S Bejarano, MPH","857-215-2365","oldy_bejarano@dfci.harvard.edu",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-71.05977,42.35843,{"lat":50,"lon":49},[53,54],{"name":26,"role":30,"phone":31,"phoneExt":32,"email":33},{"name":26,"role":27,"phone":32,"phoneExt":32,"email":32},{"type":27,"investigatorFullName":26,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Principal Investigator",[58,61],{"name":59,"class":60},"National Cancer Institute (NCI)","NIH",{"name":62,"class":6},"American Society of Clinical Oncology","100552147","driving-inclusivity-validity-and-equity-in-research-through-strategic-engagement-diverse-100552147",false,"NCT06469307","Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)","CAB Participant Inclusion Criteria:\n\n* Age 18 or older\n* English speaking\n* Ability to understand and willingness to provide oral consent\n* DFCI patient who are in remission from a blood cancer \\>1 year will be preferred.\n\nCAB Participant Exclusion Criteria:\n\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers \\\u003C18 years old)\n* Prisoners.\n* Unwilling\u002Funable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1\n* Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed.\n* Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews.\n\nInvestigator Participant Inclusion Criteria:\n\n* Age 18 older\n* English Speaking\n* Site or Principal investigator\n* Not a member of the research team",true,"ALL","18 Years",{"count":73,"type":74},40,"ESTIMATED","INTERVENTIONAL",[77],"NA","The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.",[80,81],"Blood Cancer","Leukemia",[80,81],"2026-05-26",{"date":85,"type":86},"2026-05-28","ACTUAL",{"date":88,"type":86},"2024-12-09",{"date":90,"type":74},"2027-06-30",{"name":5,"class":6},1]